Metropolitan Life Insurance CO Bluebird Bio, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

55 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.91 - $1.75 $6,258 - $12,034	6,877 Added 198.76%	10,337 $13,000
Q4 2023 Feb 14, 2024	SELL	$1.32 - $4.83 $2,838 - $10,384	-2,150 Reduced 38.32%	3,460 $4,000
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $1,463 - $3,830	466 Added 9.06%	5,610 $17,000
Q4 2022 Jun 14, 2023	SELL	$5.77 - $8.49 $2,688 - $3,956	-466 Reduced 8.31%	5,144 $35.6 Million
Q4 2022 Mar 30, 2023	BUY	$5.77 - $8.49 $2,729 - $4,015	473 Added 10.13%	5,144 $35,000
Q4 2022 Feb 15, 2023	BUY	$5.77 - $8.49 $2,729 - $4,015	473 Added 10.13%	5,144 $35,000
Q3 2022 Jun 14, 2023	SELL	$3.75 - $7.39 $3,521 - $6,939	-939 Reduced 16.74%	4,671 $29.6 Million
Q3 2022 Mar 30, 2023	BUY	$3.75 - $7.39 $10,290 - $20,278	2,744 Added 142.4%	4,671 $29,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $10,290 - $20,278	2,744 Added 142.4%	4,671 $30,000
Q2 2022 Jun 20, 2023	SELL	$2.94 - $5.23 $10,828 - $19,262	-3,683 Reduced 65.65%	1,927 $7,000
Q2 2022 Mar 30, 2023	SELL	$2.94 - $5.23 $7,591 - $13,503	-2,582 Reduced 57.26%	1,927 $7,000
Q2 2022 Aug 11, 2022	SELL	$2.94 - $5.23 $7,591 - $13,503	-2,582 Reduced 57.26%	1,927 $8,000
Q1 2022 Jun 20, 2023	SELL	$4.07 - $10.6 $4,481 - $11,670	-1,101 Reduced 19.63%	4,509 $21,000
Q1 2022 Mar 30, 2023	SELL	$4.07 - $10.6 $55,193 - $143,746	-13,561 Reduced 75.05%	4,509 $21,000
Q1 2022 May 12, 2022	SELL	$4.07 - $10.6 $55,193 - $143,746	-13,561 Reduced 75.05%	4,509 $22,000
Q4 2021 Jun 21, 2023	BUY	$8.96 - $16.31 $111,641 - $203,222	12,460 Added 222.1%	18,070 $180,000
Q4 2021 Mar 30, 2023	SELL	$8.96 - $16.31 $6,128 - $11,156	-684 Reduced 3.65%	18,070 $180,000
Q4 2021 Feb 15, 2022	SELL	$8.96 - $16.31 $6,128 - $11,156	-684 Reduced 3.65%	18,070 $181,000
Q3 2021 Jun 21, 2023	BUY	$11.24 - $21.0 $147,738 - $276,024	13,144 Added 234.3%	18,754 $232,000
Q2 2021 Jun 21, 2023	BUY	$18.04 - $22.09 $237,117 - $290,350	13,144 Added 234.3%	18,754 $388,000
Q2 2021 Mar 30, 2023	BUY	$18.04 - $22.09 $299,500 - $366,738	16,602 Added 771.47%	18,754 $388,000
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $338,286 - $414,231	18,752 Added 937600.0%	18,754 $600,000
Q1 2021 Jun 26, 2023	SELL	$16.59 - $33.89 $45,108 - $92,146	-2,719 Reduced 48.47%	2,891 $87.2 Million
Q1 2021 Mar 30, 2023	SELL	$16.59 - $33.89 $13,388 - $27,349	-807 Reduced 27.27%	2,152 $42,000
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $49,056 - $100,212	-2,957 Reduced 99.93%	2 $65,000
Q4 2020 Jun 22, 2023	SELL	$27.5 - $37.92 $72,902 - $100,525	-2,651 Reduced 47.25%	2,959 $82,000
Q4 2020 Mar 30, 2023	SELL	$27.5 - $37.92 $1,815 - $2,502	-66 Reduced 2.18%	2,959 $82,000
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $1,815 - $2,502	-66 Reduced 2.18%	2,959 $128,000
Q3 2020 Jun 26, 2023	SELL	$34.44 - $43.75 $89,027 - $113,093	-2,585 Reduced 46.08%	3,025 $105,000
Q2 2020 Jun 26, 2023	SELL	$27.12 - $45.97 $70,105 - $118,832	-2,585 Reduced 46.08%	3,025 $119,000
Q2 2020 Mar 30, 2023	BUY	$27.12 - $45.97 $45,832 - $77,689	1,690 Added 126.59%	3,025 $119,000
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $45,832 - $77,689	1,690 Added 126.59%	3,025 $185,000
Q1 2020 Jul 12, 2023	SELL	$26.16 - $63.5 $111,834 - $271,462	-4,275 Reduced 76.2%	1,335 $39,000
Q4 2019 Jul 12, 2023	SELL	$46.96 - $61.67 $200,754 - $263,639	-4,275 Reduced 76.2%	1,335 $75,000
Q4 2019 Mar 30, 2023	BUY	$46.96 - $61.67 $187 - $246	4 Added 0.3%	1,335 $75,000
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $187 - $246	4 Added 0.3%	1,335 $117,000
Q3 2019 Jul 12, 2023	SELL	$59.47 - $93.1 $254,472 - $398,374	-4,279 Reduced 76.27%	1,331 $79,000
Q3 2019 Mar 30, 2023	SELL	$59.47 - $93.1 $108,354 - $169,628	-1,822 Reduced 57.79%	1,331 $79,000
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $108,354 - $169,628	-1,822 Reduced 57.79%	1,331 $122,000
Q2 2019 Jul 12, 2023	SELL	$75.84 - $105.21 $186,338 - $258,500	-2,457 Reduced 43.8%	3,153 $259,000
Q2 2019 Mar 30, 2023	SELL	$75.84 - $105.21 $4,853 - $6,733	-64 Reduced 1.99%	3,153 $259,000
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $4,853 - $6,733	-64 Reduced 1.99%	3,153 $401,000
Q1 2019 Jul 13, 2023	SELL	$64.44 - $104.11 $154,204 - $249,135	-2,393 Reduced 42.66%	3,217 $327,000
Q1 2019 Mar 30, 2023	SELL	$64.44 - $104.11 $124,175 - $200,619	-1,927 Reduced 37.46%	3,217 $327,000
Q1 2019 May 16, 2019	SELL	$64.44 - $104.11 $8.44 Million - $13.6 Million	-131,038 Reduced 97.6%	3,217 $506,000
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $8.44 Million - $13.6 Million	130,974 Added 3991.89%	134,255 $1.49 Million
Q4 2018 Jul 13, 2023	SELL	$59.1 - $93.26 $137,643 - $217,202	-2,329 Reduced 41.52%	3,281 $210,000
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $413 - $652	-7 Reduced 0.21%	3,281 $325,000
Q3 2018 Jul 13, 2023	SELL	$88.86 - $117.49 $206,332 - $272,811	-2,322 Reduced 41.39%	3,288 $480 Million
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $13,506 - $17,858	152 Added 4.85%	3,288 $480,000
Q2 2018 Aug 15, 2018	SELL	$99.64 - $127.59 $1.21 Million - $1.55 Million	-12,180 Reduced 79.52%	3,136 $0
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $56,497 - $80,601	534 Added 3.61%	15,316 $0
Q4 2017 Feb 15, 2018	SELL	$81.25 - $130.7 $1.28 Million - $2.06 Million	-15,736 Reduced 51.56%	14,782 $2.63 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $140,192 - $221,967	2,428 Added 8.64%	30,518 $4.19 Million
Q2 2017 Aug 14, 2017	BUY	N/A	28,090	28,090 $2.95 Million

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.71 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.88 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.73 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.73 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.42 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account